請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20978
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 忻凌偉(Ling-Wei Hsin) | |
dc.contributor.author | Yen-Ting Chi | en |
dc.contributor.author | 吉彥婷 | zh_TW |
dc.date.accessioned | 2021-06-08T03:13:30Z | - |
dc.date.copyright | 2017-02-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-13 | |
dc.identifier.citation | 1. Phelps, M. E., PET: the merging of biology and imaging into molecular imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000, 41 (4), 661-81.
2. Mach, R. H., New targets for the development of PET tracers for imaging neurodegeneration in Alzheimer disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014, 55 (8), 1221-4. 3. Nordberg, A., Dementia in 2014. Towards early diagnosis in Alzheimer disease. Nat Rev Neurol 2015, 11 (2), 69-70. 4. Fischer, A.; Sananbenesi, F.; Wang, X.; Dobbin, M.; Tsai, L. H., Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447 (7141), 178-82. 5. Francis, Y. I.; Fa, M.; Ashraf, H.; Zhang, H.; Staniszewski, A.; Latchman, D. S.; Arancio, O., Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009, 18 (1), 131-9. 6. Rinne, J. O.; Brooks, D. J.; Rossor, M. N.; Fox, N. C.; Bullock, R.; Klunk, W. E.; Mathis, C. A.; Blennow, K.; Barakos, J.; Okello, A. A.; de Liano, S. R. M.; Liu, E.; Koller, M.; Gregg, K. M.; Schenk, D.; Black, R.; Grundman, M., 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology 2010, 9 (4), 363-372. 7. Braak, H.; Braak, E., Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18 (4), 351-7. 8. Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L. A.; Katzman, R., Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of neurology 1991, 30 (4), 572-80. 9. Jack, C. R.; Knopman, D. S.; Jagust, W. J.; Shaw, L. M.; Aisen, P. S.; Weiner, M. W.; Petersen, R. C.; Trojanowski, J. Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology 2010, 9 (1), 119-128. 10. Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergstrom, M.; Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausen, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresti, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.; Langstrom, B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of neurology 2004, 55 (3), 306-19. 11. Hatashita, S.; Yamasaki, H.; Suzuki, Y.; Tanaka, K.; Wakebe, D.; Hayakawa, H., [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. European journal of nuclear medicine and molecular imaging 2014, 41 (2), 290-300. 12. European Medicines Agency. Vizamyl: flutemetamol (18F). Authorisation details. 1999. . http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002557/human_med_001794.jsp&mid=WC0b01ac058001d124. 13. European Medicines Agency. Amyvid: florbetapir (18F).Authorisation details. 1999. . http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002422/human_med_001611.jsp&mid=WC0b01ac058001d124. 14. European Medicines Agency. Amyvid: florbetapir (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002422/human_med_001611.jsp&mid=WC0b01ac058001d124. 15. Graff, J.; Tsai, L. H., Histone acetylation: molecular mnemonics on the chromatin. Nature reviews. Neuroscience 2013, 14 (2), 97-111. 16. Levenson, J. M.; O'Riordan, K. J.; Brown, K. D.; Trinh, M. A.; Molfese, D. L.; Sweatt, J. D., Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004, 279 (39), 40545-59. 17. Haberland, M.; Montgomery, R. L.; Olson, E. N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10 (1), 32-42. 18. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Moroni, F.; Chiarugi, A., Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006, 70 (6), 1876-84. 19. Guan, J. S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J. H.; Joseph, N.; Gao, J.; Nieland, T. J.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J. E.; DePinho, R. A.; Jaenisch, R.; Tsai, L. H., HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459 (7243), 55-60. 20. Graff, J.; Rei, D.; Guan, J. S.; Wang, W. Y.; Seo, J.; Hennig, K. M.; Nieland, T. J.; Fass, D. M.; Kao, P. F.; Kahn, M.; Su, S. C.; Samiei, A.; Joseph, N.; Haggarty, S. J.; Delalle, I.; Tsai, L. H., An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483 (7388), 222-6. 21. Anderson, K. W.; Chen, J. J.; Wang, M. Y.; Mast, N.; Pikuleva, I. A.; Turko, I. V., Quantification of Histone Deacetylase Isoforms in Human Frontal Cortex, Human Retina, and Mouse Brain. Plos One 2015, 10 (5). 22. Wey, H. Y.; Gilbert, T. M.; Zurcher, N. R.; She, A.; Bhanot, A.; Taillon, B. D.; Schroeder, F. A.; Wang, C.; Haggarty, S. J.; Hooker, J. M., Insights into neuroepigenetics through human histone deacetylase PET imaging. Science translational medicine 2016, 8 (351), 351ra106. 23. Schroeder, F. A.; Lewis, M. C.; Fass, D. M.; Wagner, F. F.; Zhang, Y. L.; Hennig, K. M.; Gale, J.; Zhao, W. N.; Reis, S.; Barker, D. D.; Berry-Scott, E.; Kim, S. W.; Clore, E. L.; Hooker, J. M.; Holson, E. B.; Haggarty, S. J.; Petryshen, T. L., A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. Plos One 2013, 8 (8). 24. Schroeder, F. A.; Chonde, D. B.; Riley, M. M.; Moseley, C. K.; Granda, M. L.; Wilson, C. M.; Wagner, F. F.; Zhang, Y. L.; Gale, J.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M., FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett 2013, 550, 119-124. 25. Haggarty, S. J.; Tsai, L. H., Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem 2011, 96 (1), 41-52. 26. Wang, Y.; Zhang, Y. L.; Hennig, K.; Gale, J. P.; Hong, Y.; Cha, A.; Riley, M.; Wagner, F.; Haggarty, S. J.; Holson, E.; Hooker, J., Class I HDAC imaging using [ (3)H]CI-994 autoradiography. Epigenetics 2013, 8 (7), 756-64. 27. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O., Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999, 42 (15), 3001-3. 28. Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer http://www.onclive.com/web-exclusives/Breakthrough-Designation-Granted-to-Entinostat-for-Advanced-Breast-Cancer. 29. Hooker, J. M.; Kim, S. W.; Alexoff, D.; Xu, Y.; Shea, C.; Reid, A.; Volkow, N.; Fowler, J. S., Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem Neurosci 2010, 1 (1), 65-73. 30. Hendricks, J. A.; Keliher, E. J.; Marinelli, B.; Reiner, T.; Weissleder, R.; Mazitschek, R., In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem 2011, 54 (15), 5576-82. 31. Hanson, J. E.; La, H.; Plise, E.; Chen, Y. H.; Ding, X.; Hanania, T.; Sabath, E. V.; Alexandrov, V.; Brunner, D.; Leahy, E.; Steiner, P.; Liu, L.; Scearce-Levie, K.; Zhou, Q., SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. Plos One 2013, 8 (7), e69964. 32. Gopalan, B.; Ponpandian, T.; Kachhadia, V.; Bharathimohan, K.; Vignesh, R.; Sivasudar, V.; Narayanan, S.; Mandar, B.; Praveen, R.; Saranya, N.; Rajagopal, S.; Rajagopal, S., Discovery of adamantane based highly potent HDAC inhibitors. Bioorg Med Chem Lett 2013, 23 (9), 2532-7. 33. Seo, Y. J.; Kang, Y.; Muench, L.; Reid, A.; Caesar, S.; Jean, L.; Wagner, F.; Holson, E.; Haggarty, S. J.; Weiss, P.; King, P.; Carter, P.; Volkow, N. D.; Fowler, J. S.; Hooker, J. M.; Kim, S. W., Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. ACS Chem Neurosci 2014, 5 (7), 588-96. 34. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J. P., Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharmaceut Res 1999, 16 (10), 1514-1519. 35. Fan, Y.; Unwalla, R.; Denny, R. A.; Di, L.; Kerns, E. H.; Diller, D. J.; Humblet, C., Insights for Predicting Blood-Brain Barrier Penetration of CNS Targeted Molecules Using QSPR Approaches. J Chem Inf Model 2010, 50 (6), 1123-1133. 36. Ghose, A. K.; Crippen, G. M., Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 1987, 27 (1), 21-35. 37. Ottaviani, G.; Martel, S.; Carrupt, P. A., Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. J Med Chem 2006, 49 (13), 3948-54. 38. Berk, S. C.; Close, J.; Hamblett, C.; Heidebrecht, R. W.; Kattar, S. D.; Kliman, L. T.; Mampreian, D. M.; Methot, J. L.; Miller, T.; Sloman, D. L., Spirocyclic compounds as hdac inhibitors. Google Patents: 2007. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20978 | - |
dc.description.abstract | 生物體內的酵素共同調節染色質組蛋白的乙醯化程度,在細胞增生與分化的表觀遺傳調控上扮演了重要的角色。現今,許多科學家專注於研究組織蛋白去乙醯化酶(HDACs),因其影響許多重要細胞的功能,導致如癌症、神經系統退化、記憶認知障礙、藥物成癮、憂鬱症等疾病。然而,對於這些人類疾病中正常組織蛋白去乙醯化酶的密度及活性的轉變過程卻仍不完全明確,且缺乏非侵入性的方式用以追蹤生物活體投以藥物後的組織蛋白去乙醯酶作用的分布情形。因此,使用正子斷層掃描造影技術,不僅是一種非侵入性的醫學影像檢查,更能成為一套有用的工具,用以即時監測染色質調控酵素在動物或人體內的作用情形。
我們的目標為合成出多種苯甲醯胺結構之衍生物,發展組織蛋白去乙醯化酶抑制劑之前驅物合成標幟方法,從中篩選出最佳候選診斷藥物並開發成能進入腦部的正子斷層掃描造影組織蛋白去乙醯化酶放射性追蹤劑,藉由其放射性同位素特性標幟作用,從影像資訊中進一步探究其參與表觀遺傳調控及致病的機制,以及了解藥物治療效果,成為協助治療疾病的利器。 根據許多先進們在醫藥化學上的貢獻,我們參考已報導使用在能進入神經系統引起藥效的組織蛋白去乙醯化酶抑制劑藥物的化學結構,作其化學結構上的修飾,合成出具有類似的藥理活性結構,進而設計化合物10, 12系列衍生物含有多碳鏈氟的基團、化合物7系列衍生物含有金剛烷胺基團,提高化學分子能進入血腦障壁的機會。在候選的藥物設計、結構修飾的過程中,我們希望能先經由體外的化合物對組織蛋白去乙醯化酶藥理活性測試試驗以及其達抑制酵素50%活性的濃度試驗中選擇先導化合物,未來的其他目標亦會著重於為進行化合物的放射性同位素標幟作用,如:碳-11及氟-18。 | zh_TW |
dc.description.abstract | Regulating histone acetylation in vivo is an integral aspect of chromatin modulation which plays a critical role in cell proliferation and differentiation. To date, much attention to this regard has been paid to the histone deacetylase (HDAC) family of enzymes correlated with several forms of cancer and impact on CNS functions such as neuronal differentiation, memory formation, drug addiction and depression. However, our knowledge of normal HDACs density and alterations in HDACs with human disease remains limited and invasive methodologies used to investigate HDACs distribution are not compatible with translational medicine. Therefore, the non-invasive imaging technique, positron emission tomography (PET), is a valuable tool to visualize chromatin-modifying enzymes in animals and human. Our goal is to develop a PET imaging probe of novel HDAC inhibitors from the benzoylamide and ortho-aminoanilide chemical classes which can evaluate the expression and distribution of these epigenetic enzymes will improve our understanding of their relationship with disease and would provide an opportunity to intervene with treatment.
In medicinal chemistry efforts by others, mimicking the structures have been reported as the potent HDAC inhibitors or a chemical moiety frequently used developing in CNS-penetrant compounds, we designed compound 10, 12 series containing a fluoroalkyl group and compound 7 series containing an adamantyl group as a ‘blood brain barrier (BBB) carrier’. Ex vivo prioritization of compounds should be achieved using a validated functional recombinant HDAC assay and IC50 values for candidate molecules to elucidate how structural modifications impact target HDAC subtypes engagement. Furthermore, another object of the invention is to label lead compounds with radionuclides, such as Carbon-11 and Fluorine-18. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:13:30Z (GMT). No. of bitstreams: 1 ntu-106-R03423031-1.pdf: 10670805 bytes, checksum: 58aa07f97c8697646f9ebab2593b6f78 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | content (I)
中文摘要 (III) Abstract (IV) List of Figures (V) List of Tables (VI) List of Schemes (VII) List of Abbreviations (VIII) Chapter 1 Introduction (p.1) 1.1 Alzheimer Disease Neuroimaging: PET Scans(p.1) 1.2 Histone deacetylase (p.2) 1.3 HDAC inhibitors (HDACis) (p.3) 1.4 PET tracers for HDACs: (p.5) 1.5 Structural Design (p.7) Chapter 2 Result and discussion (p.16) 2.1 Chemistry (p.16) 2.1.1 Synthesis of precursor 13a (p.18) 2.1.2 Radiosynthesis of [18F]-12a (p.18) 2.2 Biological activity of target compounds (p.18) 2.3 Physicochemical profiles of target compounds(p.20) 2.3.1 Log P determination by HPLC method (p.23) 2.3.2 Blood brain barrier (BBB) permeability determination (p.26) Chapter 3 Conclusion (p.27) Chapter 4 Experimental section (p.28) 4.1 Reagents and solvents (p.28) 4.2 General instruments and methods (p.29) 4.3 Chemical procedures (p.33) Chapter 5 References (p.76) Chapter 6 Appendix (p.79) | |
dc.language.iso | en | |
dc.title | 開發新穎腦部正子斷層掃描造影組蛋白去乙醯化酶放射性追蹤劑 | zh_TW |
dc.title | Novel Histone Deacetylase Radiotracers for Brain PET Imaging | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 孔繁璐(Fan-Lu Kung),薛晴彥(Chyng-Yann Shiue) | |
dc.subject.keyword | 正子斷層掃描造影,組蛋白去乙醯化?,放射性追蹤劑,腦部, | zh_TW |
dc.subject.keyword | Histone Deacetylase,Radiotracer,Brain PET Imaging, | en |
dc.relation.page | 143 | |
dc.identifier.doi | 10.6342/NTU201700505 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-02-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 10.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。